Amundi Has $1.74 Million Stock Position in Prestige Consumer Healthcare Inc. $PBH

Key Points

• Amundi has reduced its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 19.6%, now holding 20,630 shares valued at approximately $1.74 million.
• The company reported $0.95 EPS for the last quarter, missing estimates, with revenue down 6.6% year-over-year.
• Analysts have downgraded Prestige Consumer Healthcare, with Zacks Research shifting its rating from "hold" to "strong sell".

Amundi decreased its position in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 19.6% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 20,630 shares of the company's stock after selling 5,039 shares during the period. Amundi's holdings in Prestige Consumer Healthcare were worth $1,744,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Kayne Anderson Rudnick Investment Management LLC grew its holdings in shares of Prestige Consumer Healthcare by 45.3% in the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,580,819 shares of the company's stock worth $135,903,000 after purchasing an additional 493,199 shares during the last quarter. Invesco Ltd. boosted its position in Prestige Consumer Healthcare by 24.7% in the 1st quarter. Invesco Ltd. now owns 1,321,800 shares of the company's stock valued at $113,635,000 after buying an additional 261,537 shares during the last quarter. Congress Asset Management Co. boosted its position in Prestige Consumer Healthcare by 9.1% in the 1st quarter. Congress Asset Management Co. now owns 991,580 shares of the company's stock valued at $85,246,000 after buying an additional 82,838 shares during the last quarter. Westwood Holdings Group Inc. boosted its position in shares of Prestige Consumer Healthcare by 7.1% in the 1st quarter. Westwood Holdings Group Inc. now owns 861,282 shares of the company's stock worth $74,044,000 after purchasing an additional 56,802 shares during the last quarter. Finally, Northern Trust Corp boosted its position in shares of Prestige Consumer Healthcare by 4.8% in the 1st quarter. Northern Trust Corp now owns 852,274 shares of the company's stock worth $73,270,000 after purchasing an additional 39,198 shares during the last quarter. Institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Trading Down 2.6%

Shares of NYSE:PBH opened at $63.31 on Friday. Prestige Consumer Healthcare Inc. has a 12-month low of $62.95 and a 12-month high of $90.04. The stock has a market cap of $3.12 billion, a PE ratio of 14.86, a P/E/G ratio of 2.06 and a beta of 0.46. The business has a 50 day moving average of $70.53 and a 200-day moving average of $79.23. The company has a quick ratio of 2.99, a current ratio of 4.38 and a debt-to-equity ratio of 0.55.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.95 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.01 by ($0.06). Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The firm had revenue of $249.53 million for the quarter, compared to the consensus estimate of $260.71 million. During the same quarter in the prior year, the firm earned $0.90 EPS. The company's revenue was down 6.6% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. As a group, equities research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Wall Street Analysts Forecast Growth

PBH has been the topic of several recent research reports. Zacks Research lowered Prestige Consumer Healthcare from a "hold" rating to a "strong sell" rating in a research report on Thursday, September 4th. Wall Street Zen downgraded Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Finally, Canaccord Genuity Group lowered their target price on Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $93.33.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.